PharmaCorp to Acquire a Pharmacy in Ontario for $5,300,000, New Non-Binding Letter of Intent to Acquire Two Pharmacies in Eastern Canada, Updates on Previously Announced Non-Binding Letters of Intent and Filing of Q2 Investor Presentation

Acquisition Overview - PharmaCorp has signed a definitive share purchase agreement to acquire a 100% interest in a PharmaChoice Canada bannered pharmacy business in Ontario for a purchase price of $5,300,000, expected to close around October 1, 2025 [2][3] - The company has also entered into a non-binding letter of intent to acquire two additional pharmacies in Atlantic Canada for an aggregate purchase price of approximately $6,480,000 [4][5] Strategic Importance - This acquisition is a significant milestone for PharmaCorp as it represents the first transaction completed under its charter company structure established earlier in 2025 [3] - The acquisition strategy is supported by a Strategic Alliance Agreement with PharmaChoice Canada, which is expected to enhance the company's growth and operational capabilities [3][8] Financial Details - The funding for the Ontario acquisition will be sourced from cash on hand and available funds under the corporation's credit facility [2] - The proposed acquisition in Atlantic Canada will be financed through a combination of cash, issuance of common shares, and funds from the credit facility [5] Progress on Previous Transactions - PharmaCorp has successfully closed or entered into definitive agreements for three out of four pharmacies previously announced in May 2025, with an aggregate purchase price of approximately $11,100,000 [9] - The fourth transaction, valued at approximately $1,400,000, will not proceed following due diligence [9] Future Outlook - The company remains committed to expanding its national footprint through strategic acquisitions and aims to deliver long-term value to shareholders [8]